Lung Cancer
Conference Coverage
Neoadjuvant durvalumab does not affect surgical outcomes in NSCLC: Study
AEGEAN is one of the first studies looking at immune checkpoint inhibitors in the perioperative settings that demonstrated improved EFS and pCR...
Conference Coverage
Osimertinib plus chemo ups PFS, toxicity in first line
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non–small cell lung cancer, new interim data show, but...
Conference Coverage
Surgery may worsen pleural mesothelioma survival outcomes
The first randomized, controlled trial shows greater mortality than chemotherapy alone, though surgical expertise may be a confounder.
Conference Coverage
ADCs show early promise in NSCLC
“ADCs are a new, rapidly evolving class of therapeutics, and I think that we will all have to be prepared for the future that is coming,” said Dr...
Latest News
Novel ADC offers hope in heavily pretreated NSCLC
A phase 2 trial found that almost 30% of patients receiving antibody-drug conjugate patritumab deruxtecan achieved an objective response, and...
Original Research
Adherence to Lung Cancer Screening in a Veterans Population Using Centralized and Decentralized Approaches
Original Research
Assessment of Smoking and Tobacco Use in Newly Diagnosed Veterans With Cancer: Just ASK and Beyond Just ASK: Assisting and Referring
Original Research
Clinical Impact of UV Mutational Signatures in Veterans With Cancer
Original Research
Quality Improvement Project of All Resected Lung Specimens for Pathologic Findings and Synoptic Surgical Reports for Accuracy in Staging: A Critical Review of 91 Specimens
Article
Mepolizumab improves asthma after 1 year despite comorbidities
Patients with asthma and comorbid chronic rhinosinusitis with nasal polyps showed especially significant benefits.